Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | CD274 positive |
Therapy | Ipilimumab + Nivolumab |
Indication/Tumor Type | head and neck squamous cell carcinoma |
Response Type | no benefit |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 positive | head and neck squamous cell carcinoma | no benefit | Ipilimumab + Nivolumab | Phase III | Actionable | In a Phase III trial (CheckMate 651), first-line Opdivo (nivolumab) plus Yervoy (ipilimumab) treatment did not improve overall survival (17.6 vs 14.6 mo; HR=0.78) or objective response rate (34.1 vs 36.0%) compared to EXTREME (Erbitux (cetuximab) plus Platinol (cisplatin) or Paraplatin (carboplatin) plus Adrucil (fluorouracil) followed by Erbitux (cetuximab) maintenance) in recurrent/metastatic CD274 (PD-L1)-positive (CPS>=20) head and neck squamous cell carcinoma patients (PMID: 36473143; NCT02741570). | 36473143 |
PubMed Id | Reference Title | Details |
---|---|---|
(36473143) | Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651. | Full reference... |